Meros Investment Management LP Increases Stake in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Meros Investment Management LP boosted its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 21.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,263 shares of the medical instruments supplier's stock after purchasing an additional 7,023 shares during the period. Mesa Laboratories comprises approximately 2.4% of Meros Investment Management LP's holdings, making the stock its 19th largest holding. Meros Investment Management LP owned about 0.74% of Mesa Laboratories worth $5,309,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in MLAB. Barclays PLC raised its stake in Mesa Laboratories by 357.4% in the third quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after buying an additional 6,905 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Mesa Laboratories by 27.8% during the 3rd quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier's stock worth $828,000 after acquiring an additional 1,403 shares during the period. JPMorgan Chase & Co. raised its position in shares of Mesa Laboratories by 29.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,406 shares of the medical instruments supplier's stock worth $1,092,000 after acquiring an additional 1,906 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Mesa Laboratories by 4.3% in the 4th quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 73 shares during the period. Finally, Berry Wealth Group LP boosted its position in shares of Mesa Laboratories by 5.3% during the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock valued at $219,000 after purchasing an additional 83 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Stock Up 0.9%

MLAB stock traded up $1.07 during midday trading on Friday, hitting $122.42. The stock had a trading volume of 35,545 shares, compared to its average volume of 39,820. The business has a 50-day moving average of $118.33 and a two-hundred day moving average of $126.66. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. The firm has a market cap of $665.23 million, a price-to-earnings ratio of -2.65 and a beta of 0.97. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's dividend payout ratio is -1.38%.

Insiders Place Their Bets

In other news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the completion of the transaction, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at $5,369,887.67. The trade was a 32.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.40% of the company's stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.